---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-015081"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:33:40.511881+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lipocine delays LPCN 2401 POC study, seeks FDA clarity on endpoints

## Summary
- Received IND clearance for LPCN 2401 as adjunct to GLP-1 therapy.
- Seeking regulatory clarity on POC study endpoints, including functional loss.
- POC study on hold pending FDA feedback; corporate presentation updated.
- No timeline provided for resolution; development path uncertain.

## SEC filing metadata
- accession: 0001493152-25-015081
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225015081/0001493152-25-015081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225015081/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-015081
- JSON: https://secwatch.observer/filing/0001493152-25-015081.json
- Plain text: https://secwatch.observer/filing/0001493152-25-015081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.